Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros booth and featured in a podium presentation at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Meeting on October 3, 2025, in Las Vegas, Nevada.

MagnetOs MIS sets a new standard in minimally invasive surgery as the only bone graft delivery system that is sterile, prefilled, free of human tissue, and with a mechanism of action backed by Level I clinical evidence.1,2 MagnetOs MIS ensures surgeons no longer need to compromise, meeting all critical needs for minimally invasive bone grafting:

  • Always ready when you are – single-use, sterile, and prefilled, available off the shelf with no refrigeration or thawing required1
  • Faster efficiency – graft placement three times faster than traditional funnel-based delivery methods3
  • Engineered for optimal handling – enabling easy, controlled, and precise graft placement in hard-to-reach spaces

Built on the proven science of MagnetOs and its proprietary NeedleGrip™ submicron surface technology to harness the immune system to stimulate bone formation, the MIS system is designed to maximize speed and efficiency in the operating room.4-6

Dr. Matthew Maserati, neurosurgeon at WellSpan Neurosurgery in Chambersburg, PA, will be presenting his experience with the MagnetOs MIS Delivery System at SMISS on October 3, 2025, from 9:12-9:18am in the DaVinci Ballroom. “Kuros Biosciences has delivered an elegant solution that makes MIS graft placement efficient and reliable, without compromise. I was impressed with how seamlessly the system performed and the confidence it provided in delivering MagnetOs precisely into confined spaces.” – Dr. Maserati.

Chris Fair, CEO of Kuros Biosciences, commented: “The launch of MagnetOs MIS is more than a product milestone – it reflects our vision to redefine what’s possible in spine surgery. By combining efficiency, precision, and the strength of Level I clinical evidence, we’re setting a new standard for minimally invasive care. At Kuros, our mission is to empower surgeons with innovations that don’t just keep pace with the future of surgery but help shape it.”

To learn more about the new MagnetOs MIS Delivery System, visit: www.kurosbio.com/spine/mis.

back